Commonwealth Signs Agreement with FDA
Commonwealth Informatics has signed a new contract to support the use of advanced drugs safety tools at the FDA Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research.
Commonwealth Informatics has signed a new contract to support the use of advanced drugs safety tools at the FDA Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research. This contract was a follow-up to an FDA Agreement announced in June, which includes:
- A one year commitment of ~$900K for support and consulting and four additional option years with an increasing amount each year.
- Support for one of the largest implementations of Oracle Empirica Signal as with up to 300 users accessing the suite to track the safety of marketed drugs and those in the approval process - recent batch of new drug approvals requires more safety review.
- The contract provides support for the FDA’s 21st Century regulatory review process initiative.
Read the full release here
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
